Inhibitors of the TGF-β superfamily and their clinical applications

K. Tsuchida; Y. Sunada; S. Noji; T. Murakami; A. Uezumi; M. Nakatani

doi:10.2174/138955706778742759

Inhibitors of the TGF-β superfamily and their clinical applications

K. Tsuchida, Y. Sunada, S. Noji, T. Murakami, A. Uezumi, M. Nakatani

Division for Therapies against Intractable Diseases

Research output: Contribution to journal › Review article › peer-review

32 Citations (Scopus)

Abstract

The transforming growth factor-β (TGF-β) superfamily includes TGF-β s, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-β family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-β superfamily regulate fine-tuning of activity of TGF-β family in vivo. In addition to natural inhibitors for the TGF-β family, soluble forms of receptors for the TGF-β family, blocking monoclonal antibodies and small chemical TGF-β inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-β superfamily and their medical applications.

Original language	English
Pages (from-to)	1255-1261
Number of pages	7
Journal	Mini-Reviews in Medicinal Chemistry
Volume	6
Issue number	11
DOIs	https://doi.org/10.2174/138955706778742759
Publication status	Published - 11-2006

All Science Journal Classification (ASJC) codes

Molecular Medicine
Pharmacology
Drug Discovery
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/138955706778742759

Cite this

@article{857e493b4f954c77a6ebbeb16529f717,

title = "Inhibitors of the TGF-β superfamily and their clinical applications",

abstract = "The transforming growth factor-β (TGF-β) superfamily includes TGF-β s, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-β family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-β superfamily regulate fine-tuning of activity of TGF-β family in vivo. In addition to natural inhibitors for the TGF-β family, soluble forms of receptors for the TGF-β family, blocking monoclonal antibodies and small chemical TGF-β inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-β superfamily and their medical applications.",

author = "K. Tsuchida and Y. Sunada and S. Noji and T. Murakami and A. Uezumi and M. Nakatani",

year = "2006",

month = nov,

doi = "10.2174/138955706778742759",

language = "English",

volume = "6",

pages = "1255--1261",

journal = "Mini-Reviews in Medicinal Chemistry",

issn = "1389-5575",

publisher = "Bentham Science Publishers B.V.",

number = "11",

}

TY - JOUR

T1 - Inhibitors of the TGF-β superfamily and their clinical applications

AU - Tsuchida, K.

AU - Sunada, Y.

AU - Noji, S.

AU - Murakami, T.

AU - Uezumi, A.

AU - Nakatani, M.

PY - 2006/11

Y1 - 2006/11

N2 - The transforming growth factor-β (TGF-β) superfamily includes TGF-β s, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-β family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-β superfamily regulate fine-tuning of activity of TGF-β family in vivo. In addition to natural inhibitors for the TGF-β family, soluble forms of receptors for the TGF-β family, blocking monoclonal antibodies and small chemical TGF-β inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-β superfamily and their medical applications.

AB - The transforming growth factor-β (TGF-β) superfamily includes TGF-β s, activin, myostatin and bone morphogenetic proteins. Misregulation of the activity of TGF-β family members is involved in pathogenesis of cancer, muscular dystrophy, obesity and bone and tooth remodeling. Natural inhibitors for the TGF-β superfamily regulate fine-tuning of activity of TGF-β family in vivo. In addition to natural inhibitors for the TGF-β family, soluble forms of receptors for the TGF-β family, blocking monoclonal antibodies and small chemical TGF-β inhibitors have been developed. In this review, we summarize recent advances in our understanding of inhibitors for the TGF-β superfamily and their medical applications.

UR - http://www.scopus.com/inward/record.url?scp=33750736310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750736310&partnerID=8YFLogxK

U2 - 10.2174/138955706778742759

DO - 10.2174/138955706778742759

M3 - Review article

C2 - 17100637

AN - SCOPUS:33750736310

SN - 1389-5575

VL - 6

SP - 1255

EP - 1261

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

IS - 11

ER -

Inhibitors of the TGF-β superfamily and their clinical applications

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this